Maxygen, Inc. (NASDAQ:MAXY)

CAPS Rating: 4 out of 5

A biotechnology company committed to the discovery and development of improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions.

Recs

1
Player Avatar smallcapinvest (90.78) Submitted: 12/17/2008 11:10:58 AM : Underperform Start Price: $7.10 MAXY Score: +66.63

overbought STO

Featured Broker Partners


Advertisement